Evidence map›Paper›PMID 33665679›Full record

ArticleJournal of cancer research and clinical oncology2021

Exploring the role of BAFF as biomarker in the detection of uveal melanoma metastases.

Zenan Lin, Daniela Süsskind

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF-β and TNFSF13B/VEGF-A Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zenan LinCenter for Ophthalmology, University Eye Hospital, University of Tübingen, Elfriede-Aulhorn-Strasse 7, 72076, Tübingen, Germany. zenan.lin@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0001-5501-6657
Daniela SüsskindCenter for Ophthalmology, University Eye Hospital, University of Tübingen, Elfriede-Aulhorn-Strasse 7, 72076, Tübingen, Germany.
STZ eyetrial · DE

Funding

China Scholarship Council 201708080023
6 · The paper itself

Abstract

purposeWhile B-cell activating factor (BAFF) was identified to promote the invasion in other malignancies, its role in the progression of uveal melanoma (UM) still remains unexplored. Here, we analysed the serum level of BAFF in UM patients with regard to its significance as biomarker for the metastases.

methodsIn this retrospective study, serum BAFF levels in 173 UM patients (36 with metastases and 137 without), and 23 healthy controls were measured with a multiplexed sandwich ELISA system and then correlated with clinicopathological characteristics such as primary tumor size, tumor location, histological cell type, sex, cancer stage, cytogenetic alterations of chromosome 3, and the metastatic burden. Immunohistochemical staining of 50 UM tissue specimens was also performed to evaluate the expression of BAFF and its receptors BAFF-R and TACI.

resultsThe metastatic patients were identified to have significantly higher serum BAFF levels (mean ± SD, 1520.8 ± 1182.1 pg/ml) than those without metastases (950.4 ± 494.6 pg/ml) and controls (810.3 ± 140.5 pg/ml). While no distinctions were detected with regard to tumor location, histological cell type, gender, and monosomy 3, the patients in cancer stages II, III, and IV displayed higher serum BAFF levels than those in stage I. The serum BAFF level was significantly correlated with the metastatic burden. The serum BAFF level of 1120 pg/ml was identified to have the best performance for distinguishing the metastatic patients from non-metastatic patients. In the kinetic study, we noticed that 20.8% of the analysed patients already demonstrated elevated serum BAFF concentrations before the clinical diagnosis of metastases. Positive BAFF staining was detected in the cytoplasm of single tumor cells (in 13 specimens), macrophages (in 12 specimens), and tumor-infiltrating lymphocytes (TILs) (in 13 specimens). The expressions of BAFF-R and TACI were also observed in 17 and 36 of the 50 tested UM specimens, respectively.

conclusionsOur study first suggests that BAFF might be a promising serum marker for the detection of UM metastases.

Indexed as

AdultAgedAged, 80 and overB-Cell Activating FactorBiomarkers, TumorCase-Control StudiesChromosomes, Human, Pair 3CytoplasmFemaleHumansLymphocytes, Tumor-InfiltratingMacrophagesMaleMelanomaMiddle AgedNeoplasm MetastasisB-Cell Activating FactorBiomarkers, TumorTNFSF13B protein, humanTransmembrane Activator and CAML Interactor ProteinB-cell activating factorMetastasisSerum markersTumor-infiltrating immune cellsTumor microenvironmentUveal melanoma

Identifiers

PMID33665679
PMCPMC11801909
OpenAlexW3135106638

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.